335 related articles for article (PubMed ID: 35208639)
21. Self-assessment of people with relapsing-remitting and progressive multiple sclerosis towards burden of disease, progression, and treatment utilization-Results of a large-scale cross-sectional online survey (MS Perspectives).
Bayas A; Schuh K; Christ M
Mult Scler Relat Disord; 2022 Dec; 68():104166. PubMed ID: 36115289
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
Hernandez L; O'Donnell M; Postma M;
Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
[TBL] [Abstract][Full Text] [Related]
23. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
24. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
[TBL] [Abstract][Full Text] [Related]
25. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.
Rzepiński Ł; Zawadka-Kunikowska M; Maciejek Z; Newton JL; Zalewski P
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159275
[No Abstract] [Full Text] [Related]
26. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
[TBL] [Abstract][Full Text] [Related]
27. Reliability of Isometric Muscle Strength Measurement and Its Accuracy Prediction of Maximal Dynamic Force in People with Multiple Sclerosis.
Portilla-Cueto K; Medina-Pérez C; Romero-Pérez EM; Hernández-Murúa JA; Vila-Chã C; de Paz JA
Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888667
[No Abstract] [Full Text] [Related]
28. Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis.
Conte A; Lenzi D; Frasca V; Gilio F; Giacomelli E; Gabriele M; Bettolo CM; Iacovelli E; Pantano P; Pozzilli C; Inghilleri M
J Neurol; 2009 Jun; 256(6):933-8. PubMed ID: 19252788
[TBL] [Abstract][Full Text] [Related]
29. Muscle strength and power in persons with multiple sclerosis - A systematic review and meta-analysis.
Jørgensen M; Dalgas U; Wens I; Hvid LG
J Neurol Sci; 2017 May; 376():225-241. PubMed ID: 28431618
[TBL] [Abstract][Full Text] [Related]
30. The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals.
O'Loughlin E; Hourihan S; Chataway J; Playford ED; Riazi A
Disabil Rehabil; 2017 Sep; 39(18):1821-1828. PubMed ID: 27685028
[TBL] [Abstract][Full Text] [Related]
31. Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors.
Etemadifar M; Salari M; Esnaashari A; Ghazanfaripoor F; Sayahi F; Akhavan Sigari A; Sedaghat N
Mult Scler Relat Disord; 2022 Feb; 58():103488. PubMed ID: 34999375
[TBL] [Abstract][Full Text] [Related]
32. A cross-sectional study on the relationship between cardiorespiratory fitness, disease severity and walking speed in persons with Multiple Sclerosis.
Madsen LT; Dalgas U; Hvid LG; Bansi J
Mult Scler Relat Disord; 2019 Apr; 29():35-40. PubMed ID: 30658262
[TBL] [Abstract][Full Text] [Related]
33. Information processing speed as a prognostic marker of physical impairment and progression in patients with multiple sclerosis.
Hechenberger S; Helmlinger B; Ropele S; Pirpamer L; Bachmaier G; Damulina A; Pichler A; Khalil M; Enzinger C; Pinter D
Mult Scler Relat Disord; 2022 Jan; 57():103353. PubMed ID: 35158430
[TBL] [Abstract][Full Text] [Related]
34. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
35. Profile of Polish patients with primary progressive multiple sclerosis.
Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
[TBL] [Abstract][Full Text] [Related]
36. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
37. Relationship between muscle strength parameters and functional capacity in persons with mild to moderate degree multiple sclerosis.
Kjølhede T; Vissing K; Langeskov-Christensen D; Stenager E; Petersen T; Dalgas U
Mult Scler Relat Disord; 2015 Mar; 4(2):151-8. PubMed ID: 25787191
[TBL] [Abstract][Full Text] [Related]
38. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
39. Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis.
Healy BC; Zurawski J; Chitnis T; Weiner HL; Glanz BI
Qual Life Res; 2022 Jun; 31(6):1799-1805. PubMed ID: 34783972
[TBL] [Abstract][Full Text] [Related]
40. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
